In focus: biotech and Medicare.

Watchlist biotech faces some regulatory scrutiny. Despite the FDA’s concerns being responded to in detail, analysts still question the current market valuation. We are in a “wait-and-see” mode, not rushing to buy in and waiting for a better entry.

CMS finalised 2027 Medicare Advantage payments with 2.48% increase or over $13B in additional payments, boosting health insurers’ stocks. We had a position, so we took advantage of it, locking in a nice weekly profit.